SRTS · Sensus Healthcare, Inc.
Market Cap
$48.40M
Shares
16.46M
Volume · Oct 5
16.44K
Avg daily vol (3M)
29.49K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.92
Open$3.04
Day$2.92–3.04
52W close$2.69–5.30
Avg vol 30d35K
Short int227K · 1.4% float · 8.7d
Short vol10%
Last earningsAug 13, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 14
Up next
Next earnings call
Nov 16, 2026
Est · unconfirmed
· in 6 wks
filed Aug 14, 2026
call held Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$17.51M
Trailing 12 months
Net income (TTM)
−$15.48M
Trailing 12 months
Revenue growth YoY
-68.7%
Year over year
Operating margin
-75.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-14.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$15.19M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.9%
Year over year · more shares
Price change (1Y)
-10.0%
Trailing year
Short interest
1.4%
Latest settlement · 8.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−20%
below
Price vs 50-day avg
−6%
below
RSI (14)
41
neutral
MACD trend
Negative
52-week position
9%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−8%
trailing
6-month return
−35%
trailing
YTD return
−27%
this year
Relative strength
−47%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Distributing
-9% holders QoQ · +4 funds added
Insider flow
Accumulating
Net +$563.5K over 90 days · 0% sells
Short interest
Rising
1.38% of float · ▲ +5.1% MoM · 8.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
40 holders — near 3-yr low, contrarian setup
Squeeze score
51
elevated · 0–100
Fundamentals
Revenue growth
−34%
Y/Y
Gross margin
43%
contracting
EPS growth
−215%
Y/Y
Free cash flow
$332.0K
Quant / Vol
risk profile
Volatility
65%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
4.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 6, 2020
next 12 months
Revenues
$1M
going forward
G&A expense
$1.1M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−20%
Bearish
Price vs 50-day avg
−6%
Bearish
RSI (14)
41
Neutral
MACD trend
Negative
Bearish
52-week position
9%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Distributing
-9% holders QoQ · +4 funds added
Insider flow
Accumulating
Net +$563.5K over 90 days · 0% sells
Short interest
Rising
1.38% of float · ▲ +5.1% MoM · 8.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
40 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $3
Now $3 · 9%
Range high $5
vs 200-day avg -20%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Overall gross profit percentage | 34.8% | the three months ended June 30, 2026 filing | — |
| Active website users | 153% | Q2 2026 | — |
| Adjusted EBITDA non-GAAP | $3M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net loss -8.75M
+86K Depreciation
+70K Stock compensation expense
+5.69M Income tax expense (benefit)
-117K Interest income, net
= Adjusted EBITDA -3.02M
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SRTS
this stock
Sensus Healthcare, Inc.
|
$48.40M | -26.6% | -34.3% | — | 1.4% |
|
ABT
Abbott Laboratories
|
$174.90B | -20.1% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -8.4% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -18.8% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -55.5% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SRTS | -2.5% | -8.5% | -35.0% | -2.3% | -26.6% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -3.7% | -9.1% | -46.5% | -3.9% | -40.3% |